Second allogeneic bone marrow transplantation (BMT) for AML relapsing after an initial BMT has a poor prognosis, with a probability of a 2-y disease-free survival below 30 per cent, caused both by treatment-related mortality (TRM) and high relapse rate. While TRM is most likely due to heavy pretreatment, AML relapse after BMT may be due to resistant disease or to a poor graftversus-leukaemia (GvL) effect of the transplant. The degree of GvL may depend on individual donor/recipient immunoreactivity. In most published cases of second allogeneic BMT, both transplants were performed from the same donor. Here, we describe a patient who was first transplanted for acute promyelocytic leukaemia (APL) (AML FAB M3v) from his HLA-identical brother and received intensive immunotherapy including donor lymphocytes and IL2. He remained free from GvHD 4I1, but developed CNS relapse. After a second BMT from another HLA-identical brother, he spontaneously developed GvHD III1, and has now been disease free for nearly 3 years. In this patient, long-term remission of AML relapsing after BMT was achieved by combining remission induction using an individual chemotherapy protocol with a second BMT from an alternative matched related donor and transient GvHD III1, which probably conferred a GVL effect. Bone Marrow Transplantation (2003) 32, 843-846. doi:10.1038/sj.bmt.1704225 Keywords: AML; APL; CNS-relapse; GvL Published data on second allogeneic transplants after leukaemia relapse indicate high treatment related mortalities (TRM) and relapse rates.
Published data on second allogeneic transplants after leukaemia relapse indicate high treatment related mortalities (TRM) and relapse rates. [1] [2] [3] [4] . In the most recently published series, a 2-year disease-free survival of 21% was found. 1 Munoz et al 3 reported five of 21 pediatric patients event-free at 5 years, with eight of 21 relapsing, and another eight of 21 dying from TRM. All except two had the same donor in both transplants. Bosi et al found an event-free survival of 26% at 5 years, with a TRM of 46%. 2 Late relapse, full conditioning, and remission before BMT were identified as good prognostic factors. 2 Other studies found even higher incidences of fatal complications. 4 The high rate of TRM can be attributed to heavy pretreatment in most patients. For leukaemia relapse, the main reasons may be resistant disease and an insufficient graft-versus-leukaemia (GvL) effect. Since the degree of GvL depends on the individual donor/recipient immunoreactivity, it is of interest to study cases of sequential bone marrow transplantations (BMTs) using different donors.
Acute promyelocytic leukaemia (APL) or acute myelogeneous leukaemia, FAB M3, is caused by the chromosomal translocation t(15;17) leading to a fusion protein consisting of the growth suppressor protein PML and the retinoic acid receptor-a(RARa). 5, 6 By inhibition of terminal differentiation in promyelocytes this protein leads to unlimited blast proliferation. The subtype FAB M3v, characterized by the microgranular morphology of the blasts, is associated with a high incidence of hyperleukocytosis and severe coagulopathy at presentation, and the prognosis is worse compared to that of classical APL. 7, 8 Here, we describe a paediatric patient with hypercellular (APL, AML FAB M3v), who experienced CNS relapse after first HLA-identical BMT with no GvHD and remained free from disease after a second BMT from another matched family donor after which he developed GVHD II-III1. This may be due to both effective systemic chemotherapy for remission induction and GvL immunoreactivity after second BMT.
Patient and Methods

Initial presentation and therapy
The patient, who had received continuous anticonvulsant medication from the age of 2 months because of focal epilepsy, presented at the age of 3.5 years with haematomas, hepatosplenomegaly, and pallor. Laboratory investigations revealed a leukocytosis of 56 800 Â 10 9 /l mostly leukaemic blasts, and thrombocytopenia of 14 000 Â 10 9 /l. Bone marrow (BM) and cerebrospinal fluid (CSF) examination confirmed the diagnosis of hypercellular acute promyelocytic leukaemia, subtype FAB M3v, with meningeal involvement (CSF contained 27 blasts per ml); cytogenetics revealed the translocation (15;17)(q22;q11). Initial therapy included exchange transfusions and all-trans-retinoic acid, followed by chemotherapy according to the German AML-BFM-98 protocol. 9 Full remission both in BM and CSF was achieved 5 months after start of chemotherapy.
First BMT
Although APL is not generally considered a high-risk leukaemia, a poor prognosis was assumed because of several known risk factors -initial hyperleukocytosis, purpura, CNS involvement, and the microgranular variant AML FAB M3v.
6-10 Therefore, 5 1/2 months after the initial presentation, a BMT was performed in CR1. Conditioning consisted of busulphan (4 mg/kg Â 4 days) and cyclophosphamide (60 mg/kg Â 2 days). The patient received 8.3 Â 10 8 /kg unmanipulated nucleated BM cells from his HLA-identical brother. Haematological reconstitution was prompt (neutrophils 4 500 day +19, reticulocytes 4 20% 0 day +16, platelet transfusion-dependence until day +10). The patient was discharged home on day +28. GvHD prophylaxis consisted of cyclosporin A alone, and was discontinued on day +19 in the absence of acute GvHD. From day +22 until day +51, the boy had a mild skin rash that resolved without specific therapy.
Immunotherapy and CNS-therapy, first CNS relapse
Since GvHD was absent, immunotherapy was initiated, consisting of escalating doses of donor lymphocytes. These were infused monthly from day +58 until 8 months after BMT, starting at 1 Â 10 5 /kg CD3+ cells and escalating to 2 Â 10 7 /kg, resulting in about 5 Â 10 7 /kg CD3+ cells in total. Donor lymphocyte therapy was tolerated well but GvHD did not develop. In order to enhance CNS therapy, intrathecal cytarabine was given at two-weekly intervals from month 7 after BMT. At 8 months after BMT, an asymptomatic CNS relapse was diagnosed on CSF cytology which showed 58% blast cells in four leukocytes/ml of CSF, confirmed on a second test which showed 20 blast cells/ml. BM was free of disease both on morphology and PCR for t (15;17) . Thus, a first, isolated CNS relapse was diagnosed. The boy received cranial irradiation with 18 Gy (month 8-9 after BMT) and the CSF was free of disease at the end of irradiation (both by morphology and PCR).
To stabilize remission, immunotherapy was initiated with IL2. Subcutaneous injections of IL2 were administered three times weekly starting at 300 000 U/m 2 , escalating over 2 months to a final dose of 3 000 000 U/m 2 . This therapy was tolerated well, still without signs of GvHD or toxicity. Treatment was discontinued 4 months after CNS relapse. The patient remained off therapy with no signs of disease and a normal quality of life 10 months after the CNS relapse.
Second CNS relapse and relapse therapy
At 23 months after initial diagnosis and 18 months after the first BMT, the patient presented with general weakness and repeated focal fits despite therapeutic serum levels of phenytoin. CNS examination revealed relapse of leukaemia with 15 leukocytes/ml in the CSF, 100% of which were leukaemic blasts. The BM was free of disease on morphology and PCR.
Since the boy had remained in good clinical condition, with normal liver, cardiac, and pulmonary function, a curative approach including repeat BMT was chosen.
Since isolated CNS treatment had been insufficient to maintain remission in this patient, relapse therapy was designed as an individualized protocol starting with one cycle of liposomal daunorubicin according to the German AML relapse study protocol 11 together with all-transretinoic acid. To obtain high CNS efficacy, this was followed by two cycles of topotecan; simultaneously methotrexate, prednisolone, and cytarabine were given intrathecally via a Rickham reservoir. The therapy was tolerated well and full remission, confirmed by PCR, was achieved after the first cycle of topotecan.
Second BMT
Secondary BMT was initiated for consolidation of remission, because long-term remission without BMT would be very unlikely, as indicated by the literature. 1 Since another HLA-identical brother was available, and since immunoreactivity of the first donor had been low, it was assumed that using the other brother as donor would provide an advantage.
To use agents that had not been used in the first BMT, and that are especially effective in the CNS, the boy received total body irradiation with 12 Gy and thiotepa (10 mg/kg/day Â 2 days) as conditioning. He was transplanted with unmanipulated BM from the other HLAidentical brother, and received 7.1 Â 10 8 /kg nucleated cells. Toxicity consisted of stomatitis II1. Haematological reconstitution was prompt (neutrophils 4 500 day +14, reticulocytes 4 20% 0 day +15, no platelet transfusiondependence), and the patient was discharged home on day +31.
GvHD prophylaxis consisted of cyclosporin A alone. From day +2 on, the patient had a mild skin rash devloping into isolated acute skin GvHD II1 on day +19, which resolved quickly with steroid therapy. Upon reduction of immunosuppression, acute GvHD developed on day +53, involving the skin (III1), and also the liver (I1) and gut (I1). Steroids, cyclosporin A, and methotrexate (three doses of 10 mg/m 2 ) were given. GvHD of the gut resolved, while skin and liver GvHD persisted at a limited level for several weeks, and stomatitis II1 with a dry mouth developed. Immunosuppression was tapered and finally discontinued at day +254. At this timepoint, the patient had no liver or skin symptoms of GvHD, but had mild stomatitis I1.
Present status, 2 years 9 months after the second transplant
At present, the boy is in good general condition, with a height at the 50th percentile. After regular vaccinations, he developed normal antibody titers. Blood, BM, and CSF continuously demonstrate full remission. The skin shows mild dyspigmentation, with no indurations or defects and mild onychomycosis of the fingernails. The heart, lung, and abdomen are clinically normal. He is a pupil at a regular school, and neurological testing shows mild impairment of coordination and speech.
Discussion
In this patient, the antileukaemic treatment of the relapse consisted of several elements known to be effective in AML, especially in CNS disease. Besides the intrathecal chemotherapy, the boy received topotecan, thiotepa, and TBI, which were very well tolerated despite heavy pretreatment. For a definitive cure of the disease, however, it was very important that no bone marrow relapse occured after the CNS relapse. Here, we believe that GvL also played an important role, and it may also be speculated that there was an IL2 effect in the period before the second BMT. Although, from the data presently available, topotecan is quite effective in AML, induction of continuous remission in AML by a single agent would be unlikely. [11] [12] [13] [14] With respect to the second conditioning, since CNS radiation with 18 Gy alone had not been sufficient in the primary therapy, TBI with 12 Gy was probably not the key factor in prolonging remission after the second BMT.
Although a number of recent clinical and experimental studies 1, 15 have addressed the question of GvL, both the type of effector cells and the mechanisms of effector/target recognition have not yet been fully elucidated. On the one hand, it has been shown that GvHD III1 or IV1 is correlated with a lower incidence of relapse, 16 and on the other hand, several studies indicate that both effector mechanisms and effector cells of GvHD and GvL are not the same in all cases. 17 NK cells, for example, have been shown to induce GvL, not GvHD, depending on certain HLA-class I mismatches leading to NK cell target recognition. 18, 19 In our patient, both donors were fully HLA identical, implying that an HLA-class I mismatch leading to NK cell recognition was not present. Therefore, it can be assumed that if GvL was the reason for the longterm remission, it was not mediated by NK cells but by T cells recognizing minor antigens. Here, there may exist relevant differences in donor/recipient immunoreactivity among sibling donors. 20 Based on our experience in a single patient, we conclude that a second allogeneic BMT for leukaemia relapse after first allogeneic BMT should be considered even with a fully myeloablative conditioning regimen, if the patient is in good condition and if remission of the disease can be achieved, especially, when new drugs for induction therapy are available. In patients relapsing after BMT, when no GvHD occurred after the first BMT, switching to another HLA-identical donor, if available, might be helpful in achieving higher donor/recipient immunoreactivity and a better GvL effect.
